Histopathology & Morbid Anatomy: Recent submissions
Now showing items 81-100 of 106
-
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
(2011)Background: Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops. Targeted therapies, such as tyrosine ... -
Similar chromosomal changes in cisplatin-resistant and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
(2006)Small cell lung cancer (SCLC) initially responds well to DNA damaging drugs such as cisplatin, however this is transitory as resistance normally develops. To investigate whether changes in chromosomal copy number caused ... -
THE EMT-ACTIVATOR ZEB1 IS UNRELATED TO PLATINUM DRUG RESISTANCE IN OVARIAN CANCER BUT PREDICTIVE OF SURVIVAL
(2014)Background: Ovarian cancer is treated by surgery followed by platinum/taxane combination chemotherapy. Initial response rates are high, but up to 80% of ovarian cancer patients will eventually relapse with drug-resistant ... -
A cloud computing database for data extraction in a Cochrane review
(2013)Background: An online database was needed for the Cochrane review ?Taxanes for the treatment of platinum pre-treated epithelial ovarian cancer? for several reasons. Firstly, a large amount of clinical parameters were to ... -
Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays
(Elsevier, 2012)Autoantibodies represent an attractive biomarker for diagnostic assays principally due to the stability of immunoglobulin in patient serum facilitating measurement with conventional assays. Immune responses to tumorigenesis ... -
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
(Springer, 2006)Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant ... -
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review.
(WB Saunders, 2007)Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of ... -
Understanding cisplatin resistance using cellular models.
(John Wiley, 2007)Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of ... -
A systematic review of platinum and taxane resitance from bench to clinic: An inverse relationship.
(WB Saunders, 2007)We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance. Medline was searched for 1) cell models of acquired drug ... -
A 39kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome.
(John Wiley, 2008)Transfected human ASK1 produces a 150kDa protein. However, we have detected endogenous ASK1 predominantly as 39kDa and 50kDa C-terminal and 75kDa and 110kDa N-terminal fragments in a panel of non-transfected cancer cell ... -
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
(Springer Verlag, 2009)Background: The H69CIS200 and H69OX400 cell lines are novel models of low- level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather ... -
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1.
(Bentham Science, 2009)A systematic review of cell models of acquired drug resistance not involving genetic manipulation showed that 80% of cell models had an inverse resistance relationship between cisplatin and paclitaxel[1]. Here we ... -
Correlation of p16(INK4A) expression and HPV copy number with cellular FTIR spectroscopic signatures of cervical cancer cells.
(2011)Cervical cancer, a potentially preventable disease, has its main aetiology in infection by high risk human papillomavirus (HR-HPV). Approaches to improving cervical cancer screening and diagnostic methodologies include ... -
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers.
(2009)We investigated the role of the C1772T polymorphisms in exon 12 of the Hypoxia-inducible factor-1 alpha (HIF-1alpha) gene C1772T genotype in prostate cancer (PCa) and amplification of the hypoxic response. We identified ... -
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.
(2010)BACKGROUND: Overexpression of the fatty acid synthase (FASN) gene has been implicated in prostate carcinogenesis. We sought to directly assess the oncogenic potential of FASN. METHODS: We used immortalized human prostate ... -
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.
(2009)The identification of biomarkers that distinguish between aggressive and indolent forms of prostate cancer (PCa) is crucial for diagnosis and treatment. In this study, we used cultured cells derived from prostate tissue ... -
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
(2009)PURPOSE Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern ... -
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
(2010)Although B-Raf(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressiveness is not fully understood. Using gene set enrichment analysis and in vitro and in vivo ... -
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma
(2009)Purpose: FOXA1 is a mammalian endodermal transcription factor belonging to the human forkhead box gene family that plays a role in certain tumor types. Here, we investigated the potential role of FOXA1 in human thyroid ...
